BACKGROUND: Dual contraception is important for averting HIV-1 transmission, unintended pregnancy, and maternal-to-child HIV-1 transmission. Few studies have explored contraceptive use in HIV-1 serodiscordant couples, a population at high risk for HIV-1 transmission. METHODS: Data from a prospective study of 3407 women in HIV-1 heterosexual serodiscordant partnerships were analyzed to describe use and correlates of contraception. RESULTS: Among 2298 HIV-1 seropositive women, 23.5% used contraception at enrollment and 30.2% used contraception after 24 months of follow-up; among 1109 HIV-1 seronegative women, contraceptive use decreased from 21.3% to 14.2%. For both HIV-1 seropositive and seronegative women, contraceptive use was less common among women from East Africa compared to women from southern Africa (adjusted odds ratio [AOR], 0.6; 95% confidence interval [CI], 0.5-0.8 and AOR, 0.6; 95% CI, 0.4-0.8, respectively) and more common among women with at least one child (AOR, 2.4; 95% CI, 1.7-3.4 and AOR, 2.3; 95% CI, 1.2-4.5, respectively). Condom use increased significantly during follow-up from 71.2% to 92.6% and 73.5% to 95.6% among HIV-1 seropositive and HIV-1 seronegative women, respectively, at baseline and 24 months. However, contraceptive use was associated with unprotected sexual activity among both HIV-1 seropositive and seronegative women (AOR, 1.3; 95% CI, 1.1-1.5 and AOR, 1.4; 95% CI, 1.1-1.8, respectively), although not among women who initiated contraception during follow-up. CONCLUSIONS: Counseling and provision of dual contraception should receive high priority in programs that care for women in HIV-1 serodiscordant partnerships.
BACKGROUND: Dual contraception is important for averting HIV-1 transmission, unintended pregnancy, and maternal-to-childHIV-1 transmission. Few studies have explored contraceptive use in HIV-1 serodiscordant couples, a population at high risk for HIV-1 transmission. METHODS: Data from a prospective study of 3407 women in HIV-1 heterosexual serodiscordant partnerships were analyzed to describe use and correlates of contraception. RESULTS: Among 2298 HIV-1 seropositivewomen, 23.5% used contraception at enrollment and 30.2% used contraception after 24 months of follow-up; among 1109 HIV-1 seronegative women, contraceptive use decreased from 21.3% to 14.2%. For both HIV-1 seropositive and seronegative women, contraceptive use was less common among women from East Africa compared to women from southern Africa (adjusted odds ratio [AOR], 0.6; 95% confidence interval [CI], 0.5-0.8 and AOR, 0.6; 95% CI, 0.4-0.8, respectively) and more common among women with at least one child (AOR, 2.4; 95% CI, 1.7-3.4 and AOR, 2.3; 95% CI, 1.2-4.5, respectively). Condom use increased significantly during follow-up from 71.2% to 92.6% and 73.5% to 95.6% among HIV-1 seropositive and HIV-1 seronegative women, respectively, at baseline and 24 months. However, contraceptive use was associated with unprotected sexual activity among both HIV-1 seropositive and seronegative women (AOR, 1.3; 95% CI, 1.1-1.5 and AOR, 1.4; 95% CI, 1.1-1.8, respectively), although not among women who initiated contraception during follow-up. CONCLUSIONS: Counseling and provision of dual contraception should receive high priority in programs that care for women in HIV-1 serodiscordant partnerships.
Authors: G Donders; G Bellen; D Janssens; B Van Bulck; P Hinoul; J Verguts Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-09 Impact factor: 3.267
Authors: Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones Journal: Contraception Date: 2018-02-09 Impact factor: 3.375
Authors: Lisa B Haddad; Chelsea B Polis; Anandi N Sheth; Jennifer Brown; Athena P Kourtis; Caroline King; Rana Chakraborty; Igho Ofotokun Journal: Curr HIV/AIDS Rep Date: 2014-12 Impact factor: 5.071
Authors: Kathryn Curran; Jared M Baeten; Thomas J Coates; Ann Kurth; Nelly R Mugo; Connie Celum Journal: Curr HIV/AIDS Rep Date: 2012-06 Impact factor: 5.071
Authors: Renee Heffron; Deborah Donnell; Helen Rees; Connie Celum; Nelly Mugo; Edwin Were; Guy de Bruyn; Edith Nakku-Joloba; Kenneth Ngure; James Kiarie; Robert W Coombs; Jared M Baeten Journal: Lancet Infect Dis Date: 2011-10-03 Impact factor: 25.071
Authors: Kenneth Ngure; Jared M Baeten; Nelly Mugo; Kathryn Curran; Sophie Vusha; Renee Heffron; Connie Celum; Bettina Shell-Duncan Journal: AIDS Care Date: 2014-04-29
Authors: Renee Heffron; Urvi M Parikh; Kerri J Penrose; Nelly Mugo; Deborah Donnell; Connie Celum; John W Mellors; Jared M Baeten Journal: AIDS Behav Date: 2017-07
Authors: Andrew Mujugira; Connie Celum; Robert W Coombs; James D Campbell; Patrick Ndase; Allan Ronald; Edwin Were; Elizabeth A Bukusi; Nelly Mugo; James Kiarie; Jared M Baeten Journal: J Acquir Immune Defic Syndr Date: 2016-08-15 Impact factor: 3.731